Type 2 diabetics taking metformin were LESS likely to die during a 2.8-year follow-up than non-diabetic controls leading the authors of the study to suggest that metformin might have a life-extending effect even in non-diabetics.
“Patients with type 2 diabetes initiated with metformin monotherapy had longer survival than did matched, non-diabetic controls,” the authors of the paper noted.
“This supports the position of metformin as first-line therapy and implies that metformin may confer benefit in non-diabetes.”
To say this another way, the authors of the study are suggesting that metformin might be life-extending drug in people WITHOUT diabetes.
© Copyright 2003-2017 - Larry Hobbs - All Rights Reserved.